Trelstar is a synthetic (manufactured) version of gonadotropin-releasing hormone (GnRH), a hormone found naturally in the body. GnRH controls the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland (a tiny gland located beneath the brain). LH and FSH stimulate production of testosterone in the testes.
Trelstar works by overstimulating the pituitary gland so that it stops making LH and FSH. As a result, the testes stop making testosterone. Prostate cancer cells grow in response to testosterone. By reducing levels, Trelstar helps slow the growth of prostate cancer.
Trelstar is specially formulated so that the medicine is slowly released into the bloodstream. The monthly injection slowly releases the medicine over a four-week period. The three-month injection slowly releases the medicine over a 12-week period. The six-month injection slowly releases medicine over a 24-week period.
Trelstar is not approved for use in children and has not been adequately studied in this group. Talk with your child's healthcare provider about the particular benefits and risks of using Trelstar in children.
Trelstar is used to treat prostate cancer, which primarily occurs in older males. The majority of men in clinical trials of Trelstar were aged 65 and older, so much of the information about the safety and effectiveness of this drug is based on its use in this age group.
On occasion, your healthcare provider may recommend this product for something other than advanced prostate cancer. This is known as an "off-label" use. For example, Trelstar is sometimes used off-label for: